SGH
Sivik Global Healthcare Portfolio holdings
AUM
$224M
This Quarter Return
+13.26%
1 Year Return
+5.3%
3 Year Return
+45.33%
5 Year Return
+103.79%
10 Year Return
+430.94%
AUM
$232M
AUM Growth
+$232M
(-23%)
Cap. Flow
-$146M
Cap. Flow
% of AUM
-62.8%
Top 10 Holdings %
Top 10 Hldgs %
36.64%
Holding
63
New
12
Increased
9
Reduced
17
Closed
25
Top Buys
| 1 |
Eli Lilly
LLY
|
$8.14M |
| 2 |
CTLT
CATALENT, INC.
CTLT
|
$7.92M |
| 3 |
Abbott
ABT
|
$7.07M |
| 4 |
Universal Health Services
UHS
|
$6.96M |
| 5 |
UnitedHealth
UNH
|
$6.86M |
Top Sells
| 1 |
Thermo Fisher Scientific
TMO
|
$38M |
| 2 |
Humana
HUM
|
$19.7M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$11.8M |
| 4 |
Smith & Nephew
SNN
|
$11.6M |
| 5 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
$9.55M |
Sector Composition
| 1 | Healthcare | 98.4% |
| 2 | Energy | 1.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Hologic
HOLX
$14.7B
| – | – |
-100,000
| Closed | -$5.7M |
|
52
AbbVie
ABBV
$374B
| – | – |
-13,000
| Closed | -$5.87M |
|
53
Adaptive Biotechnologies
ADPT
$1.96B
| – | – |
-50,000
| Closed | -$2.42M |
|
54
Agios Pharmaceuticals
AGIO
$2.36B
| – | – |
-40,000
| Closed | -$2.14M |
|
55
Amneal Pharmaceuticals
AMRX
$3B
| – | – |
-600,000
| Closed | -$2.86M |
|
56
AstraZeneca
AZN
$255B
| – | – |
-60,000
| Closed | -$9.21M |
|
|
BLUE
57
DELISTED
bluebird bio
BLUE
| – | – |
-35,000
| Closed | -$2.14M |
|
58
Bristol-Myers Squibb
BMY
$96.7B
| – | – |
-60,000
| Closed | -$3.81M |
|
59
BioNTech
BNTX
$24.1B
| – | – |
-40,000
| Closed | -$2.67M |
|
60
Cardinal Health
CAH
$36B
| – | – |
-75,000
| Closed | -$6.46M |
|
61
Cigna
CI
$80.2B
| – | – |
-35,000
| Closed | -$6.31M |
|
62
CRISPR Therapeutics
CRSP
$4.82B
| – | – |
-30,000
| Closed | -$2.21M |
|
63
Gilead Sciences
GILD
$140B
| – | – |
-50,000
| Closed | -$3.85M |
|